Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Generation Bio Co's Business Segments
Generation Bio Co's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q3 FY2025
Reportable Segments
1
Largest Segment
Single reportable segment
Total Revenue
$ 2
Regions Reported
-
Revenue Share by Reportable Segment - Q3 FY2025
- Single reportable segment100%
Revenue by Reportable Segment - Q3 FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single reportable segment | $ 2 | 100% |
Description of Generation Bio Co
Generation Bio Co is a biotechnology company that is dedicated to developing cutting-edge gene therapy treatments for rare genetic diseases. The company was founded in 2016 by a team of experienced scientists from top institutions like Harvard Medical School, MIT, and the Broad Institute.
The central focus of Generation Bio Co's work is to create gene therapies that utilize adeno-associated viruses (AAV) as vectors to deliver genetic payloads to specific cells in the body. This approach allows for the correction or replacement of defective genes, which is essential for the treatment of countless inherited disorders.
One of the key innovations that sets Generation Bio Co apart is its robust and versatile genetic engineering platform. This platform incorporates various techniques like directed evolution, DNA shuffling, and high-throughput screening to create novel AAV vectors that are highly effective at delivering therapeutic genes to target cells.
The company's founders have a deep commitment to pursuing safe and effective gene therapies. As such, they have developed rigorous safety protocols and are following strict guidelines set by the FDA for clinical trials. Generation Bio Co also emphasizes transparency, ethics, and the involvement of patients and families in the development process.
Currently, Generation Bio Co is working on several promising gene therapy programs across a range of genetic diseases, including hemophilia, phenylketonuria, and spinal muscular atrophy. These therapies have shown impressive results in preclinical studies and are poised to move into clinical trials in the near future.
In summary, Generation Bio Co is a biotechnology company that is focused on developing advanced gene therapies for the treatment of rare genetic diseases. The company is driven by a talented team of scientists who employ innovative technologies to create effective and safe genetic therapies. With a robust pipeline of promising therapies, Generation Bio Co is poised to make a significant impact on the field of gene therapy and the lives of millions of people around the world.
The central focus of Generation Bio Co's work is to create gene therapies that utilize adeno-associated viruses (AAV) as vectors to deliver genetic payloads to specific cells in the body. This approach allows for the correction or replacement of defective genes, which is essential for the treatment of countless inherited disorders.
One of the key innovations that sets Generation Bio Co apart is its robust and versatile genetic engineering platform. This platform incorporates various techniques like directed evolution, DNA shuffling, and high-throughput screening to create novel AAV vectors that are highly effective at delivering therapeutic genes to target cells.
The company's founders have a deep commitment to pursuing safe and effective gene therapies. As such, they have developed rigorous safety protocols and are following strict guidelines set by the FDA for clinical trials. Generation Bio Co also emphasizes transparency, ethics, and the involvement of patients and families in the development process.
Currently, Generation Bio Co is working on several promising gene therapy programs across a range of genetic diseases, including hemophilia, phenylketonuria, and spinal muscular atrophy. These therapies have shown impressive results in preclinical studies and are poised to move into clinical trials in the near future.
In summary, Generation Bio Co is a biotechnology company that is focused on developing advanced gene therapies for the treatment of rare genetic diseases. The company is driven by a talented team of scientists who employ innovative technologies to create effective and safe genetic therapies. With a robust pipeline of promising therapies, Generation Bio Co is poised to make a significant impact on the field of gene therapy and the lives of millions of people around the world.
Generation Bio Co is a prominent player in the biotechnology sector, specifically aiming to spearhead advancements in gene therapy for rare and genetic diseases. Their approach is underscored by a commitment to developing innovative and targeted treatments that address unmet medical needs. Below is an extensive overview of the segments, products, and services offered by Generation Bio Co.
Segments
1. Gene Therapy:
- The cornerstone of Generation Bios operations lies in the gene therapy segment. This segment is dedicated to creating transformative treatments that go beyond conventional therapies, particularly for rare diseases where options are limited. The company employs cutting-edge technology to facilitate the delivery of therapeutic genes, which are designed to correct or replace faulty genes at the molecular level.
2. Research and Development (R&D):
- Generation Bio invests heavily in R&D, optimized for the discovery and development of novel gene therapies. This segment is composed of a multidisciplinary team of scientists and researchers who engage in rigorous studies to understand various genetic disorders. They focus on:
- Genomic Sequencing: Utilizing advanced sequencing technologies to identify genetic mutations associated with diseases.
- Therapeutic Characterization: Analyzing the pathways and mechanisms of diseases to develop targeted therapies.
- Preclinical Studies: Conducting assessments to gauge the safety and efficacy of new therapies before they enter clinical trials.
Products
1. Non-Viral Gene Therapies:
- Generation Bio is pioneering the use of non-viral delivery systems, which are crucial for providing safer and more effective gene therapy solutions. These therapies leverage:
- Non-viral vectors: Utilization of plasmids and other non-viral methods to deliver therapeutic genes into target cells without the risks associated with viral vectors.
- Advanced Delivery Mechanisms: Employing technologies such as lipid nanoparticles and other innovative delivery formats that enhance the uptake of genetic material by cells.
2. Targeted Therapies:
- The company also specializes in targeted gene therapies that are tailored to individual patient profiles based on their specific genetic makeup. Key features include:
- Personalized Medicine: Implementing strategies to develop therapies based on a patient’s unique genetic anomalies, maximizing treatment efficacy.
- Gene Editing Tools: Utilizing cutting-edge genomic editing technologies, such as CRISPR/Cas9 or similar platforms, to modify genes precisely associated with a given condition.
Services
1. Research Services:
- Generation Bio provides comprehensive research services that facilitate the exploration and validation of gene therapy approaches. These services encompass:
- DNA Sequencing and Analysis: Utilizing high-throughput sequencing technologies to explore genetic variations and their implications on disease.
- Genetic Mutational Analysis: Identifying and characterizing specific mutations that lead to particular diseases, creating a foundation for targeted treatments.
2. Clinical Trials:
- To validate the safety and efficacy of its gene therapies, Generation Bio conducts extensive clinical trials, which involve:
- Phase I, II, and III Studies: Comprehensive testing stages to monitor patient responses and collect data to ensure the treatments are not only effective but also safe for human use.
- Patient-Centric Protocols: Designing trials specific to patient needs, optimizing both participant enrollment and healthcare outcomes.
3. Consultation Services:
- The company also offers consultation services aimed at educating patients and healthcare professionals about gene therapy options. This includes:
- In-Depth Informational Sessions: Providing detailed educational materials covering the nature of gene therapy, its benefits, risks, and expected outcomes.
- Expert Guidance: Offering recommendations tailored to individual medical cases and assisting in navigating treatment pathways, including both approved and investigational options.
Conclusion
In summary, Generation Bio Co is dedicated to pioneering advancements in gene therapy for rare and genetic diseases through a multifaceted approach that encompasses rigorous research and development, innovative product offerings, and comprehensive support services. Their commitment to the development of non-viral gene therapies and targeted treatment solutions positions them to play a vital role in the future of personalized medicine, ultimately aiming to improve the quality of life for patients afflicted by genetic conditions. With a strong emphasis on the integration of research, clinical validation, and patient support, Generation Bio Co is poised to make significant impacts in the biotechnology landscape.
Segments
1. Gene Therapy:
- The cornerstone of Generation Bios operations lies in the gene therapy segment. This segment is dedicated to creating transformative treatments that go beyond conventional therapies, particularly for rare diseases where options are limited. The company employs cutting-edge technology to facilitate the delivery of therapeutic genes, which are designed to correct or replace faulty genes at the molecular level.
2. Research and Development (R&D):
- Generation Bio invests heavily in R&D, optimized for the discovery and development of novel gene therapies. This segment is composed of a multidisciplinary team of scientists and researchers who engage in rigorous studies to understand various genetic disorders. They focus on:
- Genomic Sequencing: Utilizing advanced sequencing technologies to identify genetic mutations associated with diseases.
- Therapeutic Characterization: Analyzing the pathways and mechanisms of diseases to develop targeted therapies.
- Preclinical Studies: Conducting assessments to gauge the safety and efficacy of new therapies before they enter clinical trials.
Products
1. Non-Viral Gene Therapies:
- Generation Bio is pioneering the use of non-viral delivery systems, which are crucial for providing safer and more effective gene therapy solutions. These therapies leverage:
- Non-viral vectors: Utilization of plasmids and other non-viral methods to deliver therapeutic genes into target cells without the risks associated with viral vectors.
- Advanced Delivery Mechanisms: Employing technologies such as lipid nanoparticles and other innovative delivery formats that enhance the uptake of genetic material by cells.
2. Targeted Therapies:
- The company also specializes in targeted gene therapies that are tailored to individual patient profiles based on their specific genetic makeup. Key features include:
- Personalized Medicine: Implementing strategies to develop therapies based on a patient’s unique genetic anomalies, maximizing treatment efficacy.
- Gene Editing Tools: Utilizing cutting-edge genomic editing technologies, such as CRISPR/Cas9 or similar platforms, to modify genes precisely associated with a given condition.
Services
1. Research Services:
- Generation Bio provides comprehensive research services that facilitate the exploration and validation of gene therapy approaches. These services encompass:
- DNA Sequencing and Analysis: Utilizing high-throughput sequencing technologies to explore genetic variations and their implications on disease.
- Genetic Mutational Analysis: Identifying and characterizing specific mutations that lead to particular diseases, creating a foundation for targeted treatments.
2. Clinical Trials:
- To validate the safety and efficacy of its gene therapies, Generation Bio conducts extensive clinical trials, which involve:
- Phase I, II, and III Studies: Comprehensive testing stages to monitor patient responses and collect data to ensure the treatments are not only effective but also safe for human use.
- Patient-Centric Protocols: Designing trials specific to patient needs, optimizing both participant enrollment and healthcare outcomes.
3. Consultation Services:
- The company also offers consultation services aimed at educating patients and healthcare professionals about gene therapy options. This includes:
- In-Depth Informational Sessions: Providing detailed educational materials covering the nature of gene therapy, its benefits, risks, and expected outcomes.
- Expert Guidance: Offering recommendations tailored to individual medical cases and assisting in navigating treatment pathways, including both approved and investigational options.
Conclusion
In summary, Generation Bio Co is dedicated to pioneering advancements in gene therapy for rare and genetic diseases through a multifaceted approach that encompasses rigorous research and development, innovative product offerings, and comprehensive support services. Their commitment to the development of non-viral gene therapies and targeted treatment solutions positions them to play a vital role in the future of personalized medicine, ultimately aiming to improve the quality of life for patients afflicted by genetic conditions. With a strong emphasis on the integration of research, clinical validation, and patient support, Generation Bio Co is poised to make significant impacts in the biotechnology landscape.